← FDA DRUG APPROVALS

FDA ANDA · ANDA205439

HYDROCHLOROTHIAZIDE; VALSARTAN

Sponsor: HUAREN PHARMACEUTICAL CO LTD

APPLICATION
ANDA205439
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)

Products

HYDROCHLOROTHIAZIDE; VALSARTANNone (Tentative Approval)
HYDROCHLOROTHIAZIDE 12.5MG, VALSARTAN 320MG · TABLET · ORAL
HYDROCHLOROTHIAZIDE; VALSARTANNone (Tentative Approval)
HYDROCHLOROTHIAZIDE 12.5MG, VALSARTAN 160MG · TABLET · ORAL
HYDROCHLOROTHIAZIDE; VALSARTANNone (Tentative Approval)
HYDROCHLOROTHIAZIDE 25MG, VALSARTAN 320MG · TABLET · ORAL
HYDROCHLOROTHIAZIDE; VALSARTANNone (Tentative Approval)
HYDROCHLOROTHIAZIDE 25MG, VALSARTAN 160MG · TABLET · ORAL

Approval history

2017-09-06UNKNOWN · Original · standardTA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →